CompletedPhase 3NCT02246764
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Studying Body integrity dysphoria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aerie Pharmaceuticals
- Principal Investigator
- Theresa Heah, MDAerie Pharmaceuticals
- Intervention
- AR-13324 Ophthalmic Solution 0.02%(drug)
- Enrollment
- 93 target
- Eligibility
- 19-99 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- Nancy Ramirez, Bedminster, New Jersey, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02246764 on ClinicalTrials.govOther trials for Body integrity dysphoria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06898905Hyperfractionated Dual Equivalent Fractionated Radiation TherapyYale University
- RECRUITINGPHASE1NCT06966388Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing RadiationVirginia Commonwealth University
- RECRUITINGPHASE1, PHASE2NCT06853015Double Dose 4-AP on Functional Recovery After Spinal Cord InjuryShirley Ryan AbilityLab
- ACTIVE NOT RECRUITINGPHASE3NCT05456425A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumCloudbreak Therapeutics, LLC